BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16939809)

  • 1. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro.
    Dewey RA; Avedillo Díez I; Ballmaier M; Filipovich A; Greil J; Güngör T; Happel C; Maschan A; Noyan F; Pannicke U; Schwarz K; Snapper S; Welte K; Klein C
    Exp Hematol; 2006 Sep; 34(9):1161-9. PubMed ID: 16939809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome.
    Boztug K; Dewey RA; Klein C
    Curr Opin Mol Ther; 2006 Oct; 8(5):390-5. PubMed ID: 17078381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of human Wiskott-Aldrich syndrome protein in patients' cells leads to partial correction of a phenotypic abnormality of cell surface glycoproteins.
    Huang MM; Tsuboi S; Wong A; Yu XJ; Oh-Eda M; Derry JM; Francke U; Fukuda M; Weinberg KI; Kohn DB
    Gene Ther; 2000 Feb; 7(4):314-20. PubMed ID: 10694812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice.
    Charrier S; Stockholm D; Seye K; Opolon P; Taveau M; Gross DA; Bucher-Laurent S; Delenda C; Vainchenker W; Danos O; Galy A
    Gene Ther; 2005 Apr; 12(7):597-606. PubMed ID: 15616597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy.
    Avedillo Díez I; Zychlinski D; Coci EG; Galla M; Modlich U; Dewey RA; Schwarzer A; Maetzig T; Mpofu N; Jaeckel E; Boztug K; Baum C; Klein C; Schambach A
    Mol Pharm; 2011 Oct; 8(5):1525-37. PubMed ID: 21851067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrovirus-mediated WASP gene transfer corrects defective actin polymerization in B cell lines from Wiskott-Aldrich syndrome patients carrying 'null' mutations.
    Candotti F; Facchetti F; Blanzuoli L; Stewart DM; Nelson DL; Blaese RM
    Gene Ther; 1999 Jun; 6(6):1170-4. PubMed ID: 10455421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A partial down-regulation of WASP is sufficient to inhibit podosome formation in dendritic cells.
    Olivier A; Jeanson-Leh L; Bouma G; Compagno D; Blondeau J; Seye K; Charrier S; Burns S; Thrasher AJ; Danos O; Vainchenker W; Galy A
    Mol Ther; 2006 Apr; 13(4):729-37. PubMed ID: 16360341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Wiskott-Aldrich syndrome.
    Ochs HD; Thrasher AJ
    J Allergy Clin Immunol; 2006 Apr; 117(4):725-38; quiz 739. PubMed ID: 16630926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wiskott-Aldrich syndrome.
    Notarangelo LD; Miao CH; Ochs HD
    Curr Opin Hematol; 2008 Jan; 15(1):30-6. PubMed ID: 18043243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of WASP and Scar1/WAVE1 actin-associated proteins is differentially modulated during differentiation of HL-60 cells.
    Launay S; Brown G; Machesky LM
    Cell Motil Cytoskeleton; 2003 Apr; 54(4):274-85. PubMed ID: 12601690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel membrane cell projection defects in Wiskott-Aldrich syndrome B cells.
    Andreu N; Aran JM; Fillat C
    Int J Mol Med; 2007 Oct; 20(4):445-50. PubMed ID: 17786274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences.
    Martín F; Toscano MG; Blundell M; Frecha C; Srivastava GK; Santamaría M; Thrasher AJ; Molina IJ
    Gene Ther; 2005 Apr; 12(8):715-23. PubMed ID: 15750617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment.
    Ochs HD; Filipovich AH; Veys P; Cowan MJ; Kapoor N
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):84-90. PubMed ID: 19147084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wiskott-Aldrich syndrome iPS cells produce megakaryocytes with defects in cytoskeletal rearrangement and proplatelet formation.
    Ingrungruanglert P; Amarinthnukrowh P; Rungsiwiwut R; Maneesri-le Grand S; Sosothikul D; Suphapeetiporn K; Israsena N; Shotelersuk V
    Thromb Haemost; 2015 Apr; 113(4):792-805. PubMed ID: 25518736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis.
    Frecha C; Toscano MG; Costa C; Saez-Lara MJ; Cosset FL; Verhoeyen E; Martin F
    Gene Ther; 2008 Jun; 15(12):930-41. PubMed ID: 18323794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retroviral MDR1 gene transfer into marrow-engrafting human peripheral blood progenitor cells results in preferential transgene expression in the immature myeloid compartment rather than in mature myeloid progeny in vivo.
    Buss EC; Laufs S; Naundorf S; Kuehlcke K; Nagy KZ; Zeller WJ; Fruehauf S
    Cytotherapy; 2006; 8(6):562-9. PubMed ID: 17148033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study.
    Ferrua F; Cicalese MP; Galimberti S; Giannelli S; Dionisio F; Barzaghi F; Migliavacca M; Bernardo ME; Calbi V; Assanelli AA; Facchini M; Fossati C; Albertazzi E; Scaramuzza S; Brigida I; Scala S; Basso-Ricci L; Pajno R; Casiraghi M; Canarutto D; Salerio FA; Albert MH; Bartoli A; Wolf HM; Fiori R; Silvani P; Gattillo S; Villa A; Biasco L; Dott C; Culme-Seymour EJ; van Rossem K; Atkinson G; Valsecchi MG; Roncarolo MG; Ciceri F; Naldini L; Aiuti A
    Lancet Haematol; 2019 May; 6(5):e239-e253. PubMed ID: 30981783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction.
    Wada T; Jagadeesh GJ; Nelson DL; Candotti F
    Hum Gene Ther; 2002 Jun; 13(9):1039-46. PubMed ID: 12067437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic-specific lentiviral vectors circumvent cellular toxicity due to ectopic expression of Wiskott-Aldrich syndrome protein.
    Toscano MG; Frecha C; Benabdellah K; Cobo M; Blundell M; Thrasher AJ; García-Olivares E; Molina IJ; Martin F
    Hum Gene Ther; 2008 Feb; 19(2):179-97. PubMed ID: 18240968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity.
    Braun CJ; Boztug K; Paruzynski A; Witzel M; Schwarzer A; Rothe M; Modlich U; Beier R; Göhring G; Steinemann D; Fronza R; Ball CR; Haemmerle R; Naundorf S; Kühlcke K; Rose M; Fraser C; Mathias L; Ferrari R; Abboud MR; Al-Herz W; Kondratenko I; Maródi L; Glimm H; Schlegelberger B; Schambach A; Albert MH; Schmidt M; von Kalle C; Klein C
    Sci Transl Med; 2014 Mar; 6(227):227ra33. PubMed ID: 24622513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.